260 related articles for article (PubMed ID: 19111076)
21. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
22. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
24. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
25. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
Abdel-Aziz KF; Anderson JK; Svatek R; Margulis V; Sagalowsky AI; Cadeddu JA
J Endourol; 2006 Sep; 20(9):627-31. PubMed ID: 16999613
[TBL] [Abstract][Full Text] [Related]
26. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
27. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence.
Nicolai N; Miceli R; Necchi A; Biasoni D; Catanzaro M; Milani A; Piva L; Pizzocaro G; Stagni S; Torelli T; Salvioni R
Eur Urol; 2010 Dec; 58(6):912-8. PubMed ID: 20817343
[TBL] [Abstract][Full Text] [Related]
28. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
Carver BS; Serio AM; Bajorin D; Motzer RJ; Stasi J; Bosl GJ; Vickers AJ; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5603-8. PubMed ID: 17998544
[TBL] [Abstract][Full Text] [Related]
29. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
30. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
31. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
32. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
[TBL] [Abstract][Full Text] [Related]
33. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
[TBL] [Abstract][Full Text] [Related]
34. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
Considine S; Heaney R; Conroy R; Thornhill JA
Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
[TBL] [Abstract][Full Text] [Related]
35. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)].
Nicolai N; Necchi A; Piva L; Stagni S; Catanzaro MA; Biasoni D; Milani A; Torelli T; Salvioni R
Urologia; 2010; 77(2):84-7. PubMed ID: 20890864
[TBL] [Abstract][Full Text] [Related]
36. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
37. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.
Dieckmann KP; Anheuser P; Kulejewski M; Gehrckens R; Feyerabend B
BMC Urol; 2018 Oct; 18(1):95. PubMed ID: 30367648
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer.
Studer UE; Fey MF; Calderoni A; Kraft R; Mazzucchelli L; Sonntag RW
Eur Urol; 1993; 23(4):444-9. PubMed ID: 7687549
[TBL] [Abstract][Full Text] [Related]
39. Is modified retroperitoneal lymph node dissection alive for clinical stage I non-seminomatous germ cell testicular tumor?
Basiri A; Ghaed MA; Simforoosh N; Tabibi A; Danesh A; Nouralizadeh A; Parizi MK
Urol J; 2013; 10(2):873-7. PubMed ID: 23801470
[TBL] [Abstract][Full Text] [Related]
40. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]